Sugi Predict

Sugi Predict / Compounds / SCHEMBL501924

SCHEMBL501924

SCHEMBL501924

O=C(Nc1ccccc1)C1CC1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.85
▸ MEN1 O00255 3/20 0.85
▸ KMT2A Q03164 3/20 0.85
▸ MAPT P10636 3/20 0.85
▸ GFER P55789 1/20 0.85
▸ HPGD P15428 2/20 0.81
▸ GLA P06280 1/20 0.74
▸ LMNA P02545 3/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.71
▸ KDM4E B2RXH2 1/20 0.71
▸ NPC1 O15118 1/20 0.71
▸ CASP3 P42574 1/20 0.71
▸ RAB9A P51151 1/20 0.71
▸ SENP7 Q9BQF6 1/20 0.71
▸ NAMPT P43490 1/20 0.66
▸ POLB P06746 1/20 0.61
▸ YAP1 P46937 1/20 0.61
▸ TEAD4 Q15561 1/20 0.61
▸ ME3 Q16798 1/20 0.61
▸ USP2 O75604 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29675219 1.00 GAA (0.85) GAAMEN1KMT2AMAPTGFER
SCHEMBL10055001 1.00 GAA (0.85) GAAMEN1KMT2AMAPTGFER
Hydrochloric Acid SCHEMBL1804763 0.98 GAA (0.82) GAAMEN1KMT2AMAPTGFER
SCHEMBL4668488 0.92 HPGD (0.96) GAAMEN1KMT2AMAPTGFER
SCHEMBL2184247 0.92 HPGD (0.89) GAAMEN1KMT2AMAPTGFER
SCHEMBL3211102 0.91 GAA (0.72) GAAMEN1KMT2AMAPTGFER
SCHEMBL13533520 0.91 MAPT (0.72) GAAMEN1KMT2AMAPTGFER
SCHEMBL3211109 0.91 GAA (0.72) GAAMEN1KMT2AMAPTGFER
SCHEMBL19703413 0.90 HPGD (1.00) GAAMEN1KMT2AMAPTGFER
SCHEMBL1300190 0.90 HPGD (1.00) GAAMEN1KMT2AMAPTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111606820-B Preparation method of N-iodobenzene-N-phenylamide compound 湖北工业大学 2023-03-31 — — CN claimed
CN-111606820-A Preparation method of N-iodobenzene-N-phenylamide compound 湖北工业大学 2020-09-01 — — CN claimed
US-9828369-B2 Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 MERCK SHARPE & DOHME CORP. (US) 2017-11-28 — — US claimed
US-20170275274-A1 ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2017-09-28 — — US claimed
US-20170273965-A1 TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2017-09-28 — — US claimed
EP-3188732-A1 TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 Merck Sharp & Dohme Corp. (US) 2017-07-12 — — EP claimed
EP-3188731-A1 ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 Merck Sharp & Dohme Corp. (US) 2017-07-12 — — EP claimed
EP-3157914-A1 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES Bayer Pharma Aktiengesellschaft (DE) 2017-04-26 — — EP claimed
WO-2016036638-A1 ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2016-03-10 — — WO claimed
WO-2016036633-A1 TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2016-03-10 — — WO claimed
EP-2346336-A1 PESTICIDAL COMBINATIONS CONTAINING SULFOXAFLOR Syngenta Participations AG (CH) 2011-07-27 — — EP claimed
US-20110123434-A1 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS, INC (US) 2011-05-26 — — US claimed
WO-2010052129-A2 PESTICIDAL COMBINATIONS SYNGENTA PARTICIPATIONS AG (CH) 2010-05-14 — — WO claimed
WO-2010040623-A1 PESTICIDAL COMBINATIONS CONTAINING SULFOXAFLOR SYNGENTA PARTICIPATIONS AG (CH) 2010-04-15 — — WO claimed
US-20100087440-A1 Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use EXELIXIS, INC. 2010-04-08 — — US claimed
EP-2118064-A2 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS AERIE PHARMACEUTICALS, INC. (US) 2009-11-18 — — EP claimed
WO-2008086269-A2 6-AMINOISOQUINOLINE COMPOUNDS USEFUL AS KINASE MODULATORS AERIE PHARMACEUTICALS, INC. (US) 2008-07-17 — — WO claimed
JP-2002541138-A — — 2002-12-03 — — JP claimed
EP-1165500-A1 AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE Du Pont Pharmaceuticals Company (US) 2002-01-02 — — EP claimed
WO-2000059874-A1 NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE DU PONT PHARMACEUTICALS COMPANY (US) 2000-10-12 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087440-A1 Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use PIK3CA, PIK3CB, PIK3CG GAA 1284/4885MEN1 3161/4885KMT2A 2013/4885
US-20170273965-A1 TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 DGAT2, DGAT1, MOGAT2 GAA 323/4885MEN1 4539/4885KMT2A 457/4885
US-20110123434-A1 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER TP53, PHKG1, TNNI3K GAA 1936/4885MEN1 1197/4885KMT2A 1079/4885
US-20170275274-A1 ISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 DGAT2, DGAT1, MOGAT2 GAA 247/4885MEN1 4663/4885KMT2A 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.